Diabetes Injection
- All
- News
- Web Stories
-
Breakthrough: Peptide Pills Likely To Make Daily Insulin Injections Unnecessary Soon
Scientists have developed a peptide-based oral insulin delivery system that could replace daily injections. The innovation helps insulin survive digestion and enter the bloodstream, offering hope for easier diabetes management.
-
Ozempic Copycats Arrive: From Rs 11,000 To Rs 3,000, How Patent Expiry Is Reshaping Diabetes Treatment
With patent protection ending, Indian companies have moved quickly to introduce lower-cost versions with monthly therapy expected at around Rs 3,000 to Rs 4,000 for initial doses
-
Weight Loss Injection For ₹900? Three Pharma Firms Launch Affordable Semaglutide, Check Prices
Indian pharmaceutical companies have launched affordable versions of semaglutide injections following a patent expiry, significantly lowering costs for diabetes and weight management treatment and improving access for millions of patients.
-
Indian Pharma Giants Launch Low-Cost Generic Semaglutide Injections For Diabetes, Weight Management
New Delhi, March 21 (IANS) Three Indian pharmaceutical companies have launched generic versions of semaglutide injections, after the drug’s patent expired, offering lower‑cost options for patients managing Type 2 diabetes and obesity.
-
Semaglutide Patent Expires: Will Diabetes, Weight-Loss Treatment Become More Accessible For Patients?
Patent expiry does not signal a change in the medicine itself. Rather, it marks the beginning of wider competition, which typically leads to price reductions and improved availability.
-
Semaglutide Is Not A Quick Fix: Bariatric Surgeon Explains The Right Way To Use It
With generics poised to make semaglutide widely accessible in India, this medication has the potential to transform obesity care. But it cannot replace personalised, long-term treatment plans.
-
From Diabetes To Weight Loss: How Semaglutide Became The Blockbuster Behind Ozempic, Wegovy
From a diabetes drug to a global weight-loss phenomenon, semaglutide has reshaped modern medicine. As patents expire, cheaper versions may expand access, raising questions about affordability, safety and long-term impact.
-
Popular Weight Loss Drugs May Help Reduce Risk of Substance Use Disorders, Suggests New Study
A new study published in The BMJ says that GLP-1 drugs may help prevent and treat substance use disorders across all major addictive substances that were studied.
-
Abbott, Novo Nordisk India Partner Up To Launch Second Brand Of Ozempic, Widen Access To Diabetes Drug
Abbott has entered into a commercialisation agreement with Novo Nordisk India to market a second brand of semaglutide, Extensior, in India
-
Stem Cell Therapy Breakthrough: Type 2 Diabetes Reversed In Historic Case In China
Chinese scientists have achieved the world's first reversal of type-2 diabetes using stem-cell therapy. Here is what you need to know about the breakthrough and why it matters for the world and for India.
-
Breakthrough: Peptide Pills Likely To Make Daily Insulin Injections Unnecessary Soon
Scientists have developed a peptide-based oral insulin delivery system that could replace daily injections. The innovation helps insulin survive digestion and enter the bloodstream, offering hope for easier diabetes management.
-
Ozempic Copycats Arrive: From Rs 11,000 To Rs 3,000, How Patent Expiry Is Reshaping Diabetes Treatment
With patent protection ending, Indian companies have moved quickly to introduce lower-cost versions with monthly therapy expected at around Rs 3,000 to Rs 4,000 for initial doses
-
Weight Loss Injection For ₹900? Three Pharma Firms Launch Affordable Semaglutide, Check Prices
Indian pharmaceutical companies have launched affordable versions of semaglutide injections following a patent expiry, significantly lowering costs for diabetes and weight management treatment and improving access for millions of patients.
-
Indian Pharma Giants Launch Low-Cost Generic Semaglutide Injections For Diabetes, Weight Management
New Delhi, March 21 (IANS) Three Indian pharmaceutical companies have launched generic versions of semaglutide injections, after the drug’s patent expired, offering lower‑cost options for patients managing Type 2 diabetes and obesity.
-
Semaglutide Patent Expires: Will Diabetes, Weight-Loss Treatment Become More Accessible For Patients?
Patent expiry does not signal a change in the medicine itself. Rather, it marks the beginning of wider competition, which typically leads to price reductions and improved availability.
-
Semaglutide Is Not A Quick Fix: Bariatric Surgeon Explains The Right Way To Use It
With generics poised to make semaglutide widely accessible in India, this medication has the potential to transform obesity care. But it cannot replace personalised, long-term treatment plans.
-
From Diabetes To Weight Loss: How Semaglutide Became The Blockbuster Behind Ozempic, Wegovy
From a diabetes drug to a global weight-loss phenomenon, semaglutide has reshaped modern medicine. As patents expire, cheaper versions may expand access, raising questions about affordability, safety and long-term impact.
-
Popular Weight Loss Drugs May Help Reduce Risk of Substance Use Disorders, Suggests New Study
A new study published in The BMJ says that GLP-1 drugs may help prevent and treat substance use disorders across all major addictive substances that were studied.
-
Abbott, Novo Nordisk India Partner Up To Launch Second Brand Of Ozempic, Widen Access To Diabetes Drug
Abbott has entered into a commercialisation agreement with Novo Nordisk India to market a second brand of semaglutide, Extensior, in India
-
Stem Cell Therapy Breakthrough: Type 2 Diabetes Reversed In Historic Case In China
Chinese scientists have achieved the world's first reversal of type-2 diabetes using stem-cell therapy. Here is what you need to know about the breakthrough and why it matters for the world and for India.
